Ontology highlight
ABSTRACT:
SUBMITTER: Wang Y
PROVIDER: S-EPMC7125355 | biostudies-literature | 2020 Apr
REPOSITORIES: biostudies-literature
Wang Yuting Y Zhang Lenghe L Tang Xia X Luo Jinfeng J Tu Zhengchao Z Jiang Kaili K Ren Xiaomei X Xu Fang F Chan Shingpan S Li Yuhua Y Zhang Zhang Z Ding Ke K
Translational oncology 20200401 4
GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concentrations below 10 nM, GZD824 significantly suppresses FLT3, FGFR1 and PDGFRα kinase activities and inhibits their signal pathways in MV4-11<sup>Flt3-ITD</sup>, KG-1<sup>FGFR1OP2-FGFR1</sup> and EOL-1<sup>FIP1L1-PDGFRa</sup> leukemia cells. It selectively inhibi ...[more]